Showing results (281-290 of 336) with videos related to

Sort By:
Pageof 34
Transplantation Proceedings|April 1, 2008
Sex-based differences in vascular repair with bone marrow cell therapy: relevance of regulatory and Th2-type cytokinesA G Zenovich, A Panoskaltsis-Mortari, G J Caron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2002
Prognostic variables for response and outcome in patients with extragonadal germ-cell tumorsJ T Hartmann, C R Nichols, J-P Droz, et al.
Cancer|March 26, 1999
Treatment outcome of patients with brain metastases from malignant germ cell tumorsS D Fosså, C Bokemeyer, A Gerl, et al.
Oncoimmunology|July 2, 2021
Increased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AMLF Brauneck, F Haag, R Woost, et al.
Bone Marrow Transplantation|April 4, 2000
Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infectionH Einsele, H Hebart, C Kauffmann-Schneider, et al.
Cancer|June 22, 2000
The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumorsJ T Hartmann, C R Nichols, J P Droz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Clinical impact of germ cell tumor cells in apheresis products of patients receiving high-dose chemotherapyC Bokemeyer, A J Gillis, K Pompe, et al.
Journal of Clinical Pathology|May 29, 2009
HER-2/neu analysis in breast cancer bone metastasesJ Zustin, K Boddin, M C Tsourlakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 10, 2010
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)G Daugaard, I Skoneczna, N Aass, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 19, 2011
Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative studyK Oechsle, F Honecker, T Cheng, et al.
Pageof 34